| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 10 Feb 2025 | 31 Jan 2025 |
| SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve financial results for the quarter and nine months ended December 31 2024 Financial Results for the quarter and nine months ended December 31, 2024 (As Per Bse Announcement Dated on 10.02.2025) | ||
| Board Meeting | 4 Nov 2024 | 25 Oct 2024 |
| SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. Outcome of Board Meeting for Unaudited Financial Results for the Quarter and Half year ended September 30, 2024 (As Per BSE Announcement dated on 04.11.2024) Clarification - Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 05.11.2024) | ||
| Board Meeting | 5 Aug 2024 | 29 Jul 2024 |
| SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 inter alia to consider and approve the Standalone and Consolidated Financial Results of the Company for the first quarter ended June 30 2024 Outcome of Board Meeting for Unaudited Financial Results for the quarter ended June 30, 2024 Financial Results for the quarter ended June 30 2024 (As per BSE Announcement Dated on 05/08/2024) | ||
| Board Meeting | 15 Jul 2024 | 15 Jul 2024 |
| Disclosure under Regulation 30 of LODR regarding appointment of Ms. Vidhi Shanghvi as an Additional Non-Executive, Non-Independent Director | ||
| Board Meeting | 24 May 2024 | 17 May 2024 |
| SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve As attached Outcome of Board Meeting (As Per BSE Announcement dated on 24.05.2024) | ||
At the operating level, the EBITDA loss amounted to ₹102.9 Crore, a worsening from a loss of ₹91.4 Crore in the previous fiscal quarter.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
